{
  "docId": "019de075-37cf-77a8-ac06-803553b19741",
  "docSlug": "fb1f3d8675ea71173cb7fbde0c578736",
  "documentTitle": "Sarissa Capital | Activist Presentation Deck | 36 slides",
  "authorId": "sarissa-capital",
  "authorName": "Sarissa Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 36,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Uses historical precedent to justify current activist demands.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-37cf-77a8-ac06-803553b19741/9",
  "deckHref": "/decks/019de075-37cf-77a8-ac06-803553b19741",
  "deckJsonHref": "/decks/019de075-37cf-77a8-ac06-803553b19741.json",
  "deckAnchorHref": "/decks/019de075-37cf-77a8-ac06-803553b19741#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "callout",
      "text": "How Alkermes spins oncology is important → separation must be done to create shareholder value. Sarissa has a history of generating shareholder value through company spin-offs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02bfe3c2-80d8-4316-a103-46ef880bb35b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "callout",
      "text": "The two post-spin companies should be completely separate entities without cross-ownership. Each company should have modern, shareholder-friendly governance... Capital allocation should be optimal.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18ec80f3-2254-4bff-88ec-7c3cb8bc3923",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Sarissa Capital Issues Statement On Ironwood Pharmaceuticals... We also advocated for the spin of Bioverativ from Biogen which created $11.6 billion of value...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4afe83a-9387-434d-b133-811918338911",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*Sources: Ironwood/Cyclerion Press Release; Biogen/Bioverativ Press Release",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce113f12-dce2-4f5e-891f-f1078fcaac22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "table",
      "text": "Sarissa led spin-off deals: Ironwood/Cyclerion and Biogen/Bioverativ",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0527c0d-e202-441c-ad54-b4cfab75713a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Alkermes would benefit significantly with shareholders on the board to optimize the oncology new company spin-off",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27339045-46dc-41ac-b020-6df86ebcf886",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "166e9227-14ce-45bf-85d1-fbaf95d9b6c2",
      "evidence": "Citing past successful deals to build credibility",
      "confidence": 0.85
    },
    {
      "name": "breakup-spinoff",
      "slug": null,
      "matchId": "600eadb7-337c-4819-9d4a-69675dbfcd81",
      "evidence": "Advocating for spin-off to unlock shareholder value",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 3,
      "beatId": "5cb3941b-d4ad-484f-b3ac-a4caf17db8b4",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Monster",
      "beatSlug": "overcoming-monster-the-monster",
      "evidence": "Slides 3-12 present a critique of Alkermes' leadership and performance",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}